![]() In the ITT population, nivolumab was found to significantly prolong DFS with a median of 21.0 months compared with 10.9 months with placebo (HR, 0.70 95% CI, 0.54-0.89 P =.0006). Non-urothelial tract recurrence-free survival (NUTRFS) in both patient populations was a secondary end point. The primary end point was DFS in all randomized patients (the intention-to-treat population) and in those with PD-L1 tumor expression of at least 1%. Patients who had not received prior neoadjuvant cisplatin must have been ineligible for it or refused it. CheckMate 274 investigators randomly assigned 353 patients with MIUC to receive either nivolumab (n=140) or placebo (n=142) for up to 1 year of adjuvant treatment. This trial was sponsored by Bristol Myers Squibb, Checkmate 274.Therefore, the aim of the CheckMate 274 trial ( NCT02632409) was to evaluate adjuvant nivolumab in patients with high-risk MIUC after radical surgery. “As physicians, we consistently strive to provide our patients with the most effective therapies and give those with advanced disease more options,” said Dr. In 2021, it is estimated that there will be nearly 17,000 deaths due to bladder cancer in the United States - and numbers are expected to rise significantly in the next decade. Without treatment, bladder cancer can be an aggressive disease. MSK physicians have extensive experience using immunotherapy to treat people with melanoma, kidney cancer, lung cancer, and other cancers as well as handling immune-related side effects. MSK has been at the epicenter of discoveries in the field, and the institution’s work is bringing exciting new treatment options to people around the world. Since then, physician-scientists across MSK have led the effort to develop immune-based treatments for different types of cancer. Making Pioneering Advances for Bladder Cancer PatientsĬancer immunotherapy was born at MSK a little over a century ago. We are hoping this treatment will get approval for all patients at high risk of recurrence after the US Food and Drug Administration has done a detailed review of all the data,” said Dr. “The trial demonstrates that novel therapies can be identified as having patient benefit when the studies are conducted in a very rigorous fashion. The primary endpoints of disease-free survival in the study population and disease free-survival in the subset of patients with PD-L1-positive tumors were met, and these findings are highly statistically significant and clinically relevant for a population of patients with a clear unmet medical need. Bajorin and colleagues concluded that the survival data is not yet mature and will need additional research and follow-up. ![]() These cancers are often referred to as “bladder cancer” because most of them start in the bladder.ĭr. Urothelial cancers are tumors that start in the lining of the urine-collecting system that transports urine from the kidneys to the outside of our bodies. These findings have the potential to change the standard of care for bladder cancer.” ![]() Bajorin, first and corresponding author of the study. “Despite available therapies for advanced metastatic bladder cancer, new options are needed to improve long-term disease control and patient survival. “We are very encouraged by the data and the results of the study,” said Dr. Participants who received nivolumab had disease-free survival of 21 months compared with 10.9 months in people receiving the placebo. This is because no chemotherapy or immunotherapy has previously been shown to be of benefit. The current standard of care following surgery that removes the bladder or kidney and ureter has been observation without adjuvant therapy - even in patients at high risk of recurrence and death. Bajorin and investigators found that in high-risk patients, nivolumab reduced recurrence after surgery compared to patients who received the placebo. Bajorin and a team of investigators evaluated 709 patients who were at high risk for recurrence of urothelial cancer after removal of their bladder, ureter, or kidney for high-grade cancer. To evaluate for benefit, patients were randomized to receive either nivolumab or a placebo every two weeks for one year. Patients and physicians were blinded to the treatment. Both safety and quality of life were evaluated.ĭr. This research was published today in the New England Journal of Medicine. New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |